Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL; n = 28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-patient extension cohort received 50 µg/kg every o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Kreitman, Robert J., Tallman, Martin S., Robak, Tadeusz, Coutre, Steven, Wilson, Wyndham H., Stetler-Stevenson, Maryalice, FitzGerald, David J., Santiago, Linda, Gao, Guozhi, Lanasa, Mark C., Pastan, Ira
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Clinical Trials And Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969375/
https://ncbi.nlm.nih.gov/pubmed/29487070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-803072
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia